Aquestive reports Q3 2022 revenue $11.5M, net loss $12.5M; licensing deals and AQST-109 progress

Aquestive Therapeutics, Inc.

2022-Q3 EPS reported -$0.90 revenue$36,998,000

Total revenues $11.5M (down from $13.3M Q3 2021); net loss $12.5M ($0.23/share) vs $14.6M ($0.37) prior year.
Cash $18.6M; reaffirms FY2022 revenue guidance $46-49M and adjusted EBITDA loss $37-43M.
AQST-109 epinephrine film: positive EPIPHAST II data; FDA EoP2 meeting scheduled Q4 2022.
Licensing deals: Pharmanovia (Libervant EU/UK/MENA) $3.5M upfront; Otter/Assertio (Sympazan) $9M upfront + $6M milestone; Haisco (Exservan China) $7M upfront.
Appointed Dr. Kenneth Truitt as CMO; Timothy Morris to board; exploring out-licensing Libervant North America.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aquestive Therapeutics, Inc. updated its third quarter ended September 30, 2022 guidance (reaffirmed).

Period: third quarter ended September 30, 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On November 1, 2022, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business.

View on SEC.gov

Browse all earnings releases →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027568

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.